Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+34.28%
+6.50%
-6.76%
+1.93%
+1.43%
PROF
Profound Medical Cor
$5.68
Login to see Profound Medical Cor (PROF) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Earnings are forecast to grow
Trading below its fair value
Chart
$3.87 (+46.77%)
$5.75 (-1.22%)
$4.07 (+39.56%)
$7.31 (-22.30%)
PROF has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Price under $5
Low volume
PROF overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Below analyst estimate
Loss widens YoY
Income decline YoY
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Trading below its fair value
PROF Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
PROF Street view is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayPROF Earnings
The TTM reflects 12-month period, providing review of PROF financial performance.
The company financial health has moderately improved over the past year
Financial Score
SYK
370.50
+1.12%
MMSI
84.21
+2.12%
IINN
1.20
+1.69%
BSX
97.32
+1.12%
What is PROF current stock price?
What are PROF stock strengths?
What risks are associated with PROF stock?
When is PROF next earnings report?
What is PROF market cap and volume?
What is PROF's current Stock IQ?
Should I buy PROF stock right now?
Is PROF a Strong Buy right now?
What does a 'Strong Buy' rating mean for PROF?
What does a 'Strong Sell' rating mean for PROF?
What factors influence PROF's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+34.28%
+6.50%
-6.76%
+1.93%
+1.43%
PROF
Profound Medical Cor
Current Price
$5.68
Stock Insights
Strengths
Earnings are forecast to grow
Trading below its fair value
Linked to PROF
SYK
370.50
+1.12%
MMSI
84.21
+2.12%
IINN
1.20
+1.69%
BSX
97.32
+1.12%
Login to unlock Profound Medical Cor (PROF) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$3.87 (+46.77%)
$5.75 (-1.22%)
$4.07 (+39.56%)
$7.31 (-22.30%)
PROF Analysts Opinion
PROF Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Below analyst estimate
Loss widens YoY
Income decline YoY
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Trading below its fair value
PROF Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
PROF Street view is extremely bullish and have positive views on the near-term outlook
PROF has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Price under $5
Low volume
Average key support and resistance price levels.
Login to displayPROF Earnings
The TTM data reflects the most recent 12-month period, providing overview of PROF financial performance.
PROF Financial Health
The company financial health has moderately improved over the past year
Financial Score
PROF Latest Analysis
Global Release of Documentary The Path to Peace. BEIJING Sept. 30 2025 /PRNewswire/ -- How can we safeguard peace in todays turbulent world? A newly released documentary The Path to Peace produced by China Review Studio tackles this profound question about peace through compelling real-life individual stories and case studies....
Tue Sep 30, 2025
Profound Medical rises as TULSA procedure launched at Dallas Medical Center.
Tue Sep 23, 2025
Innocan Pharma Partners With a Sanctuary For Injured Animals to Bring Remedy and Hope with its LPT-CBD injection. HERZLIYA ) (FSE: IP4) (OTCQB:) (".Innocan". or the ".Company".) a pioneer in the pharmaceutical and biotechnology industries is pleased to announce its ongoing collaboration with Freedom Farm a sanctuary dedicated to rescuing animals that were expelled from the industrial farms as a result of the animals having physical disabilities and other medical conditions. Through t
Thu Sep 18, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
PROF Stock trends
PROF Stock performance
PROF Stock analysis
PROF investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings